HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
Cervical cancer screening
HPV genotyping
human papilloma virus
molecular pathology
virology
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
18
03
2019
accepted:
05
08
2019
pubmed:
14
8
2019
medline:
28
10
2019
entrez:
13
8
2019
Statut:
ppublish
Résumé
Since 2012, testing high-risk (HR)HPV has been used as the primary screening test for women ≥35 years attending the organized cervical cancer screening program in the city of Tampere. We evaluated the contribution of HPV16/18 genotyping. Data from 2012 and 2013, and the follow-up samples in 2013 and 2014, respectively, were analyzed. Abbott RealTime High-Risk HPV test detecting 14 HRHPV genotypes combined with concurrent genotyping for HPV16 and HPV18 was used. HPV was positive in 794 samples out of 11 346 HPV tested women (7%). HPV16/18 was represented in 22% of HPV-positive cases. Negative cervical cytology (NILM) was reported in 51% of HPV-positive samples. HPV16/18 genotype was accompanied with 50% of HSIL/ASC-H cases. The predominance of HPV16/18 in higher grade lesions was even more evident in cervical biopsies as 57% of CIN3 cases were associated with HPV16/18, and only 20% of carcinomas were associated with nonspecified high-risk (NSHR) genotypes. In agreement with previous studies HPV16/18 genotypes caused higher grade cytological and histological changes/pathologies than NSHR genotypes in primary screening. Nevertheless, the majority of HRHPV genotypes detected in the screened population were nonHPV16/18, and especially within persistent infections, precancerous lesions were found also among women with NSHR genotypes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
710-716Informations de copyright
© 2019 APMIS. Published by John Wiley & Sons Ltd.
Références
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
Lees BF, Erickson BK, Huh WK. Cervical cancer screening: evidence behind the guidelines. Am J Obstet Gynecol 2016;214:438-43.
Armaroli P, Villain P, Suonio E, Almonte M, Anttila A, et al. European code against cancer, 4th edition: cancer screening. Cancer Epidemiol 2015;39(Suppl 1):S139-52.
Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 2014;18:1-196.
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research. Available from: http://www.cancersociety.fi/ (Accessed 10/01/2019).
Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life up to the year 2017. Acta Oncol 1997;36(Suppl 9):1-60.
Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-46.e11.
Bosch FX, de Sanjosé S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003: 3-13.
Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602-10.
Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DA, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. J Cancer Epidemiol Biomarkers Prev 2014;23:55-63.
Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136:578-86.
Veijalainen O, Kares S, Kujala P, Tirkkonen M, Vuento R, et al. Human papillomavirus test with cytology triage in organised screening for cervical cancer. Acta Obstet Gynecol Scand 2016;95:1220-7.
The Bethesda System for Reporting Cervical Cytology, 2nd ed. Springer International Publishing Switzerland 2015, Cham: Springer.
Poljak M, Oštrbenk A. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies. Acta Dermatovenerol Alp Pannonica Adriat 2013;22:43-7.
Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocian PJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 2015;21:817-26.
Cervical Cancer Screening Current Care Guidelines. Working group set up by the Finnish Medical Society. The Finnish Medical Society Duodecim; 2016. Available at: www.kaypahoito.fi
Von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 2015;1:22-31.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
Leinonen MK, Anttila A, Malila N, Dillner J, Forslund O, Nieminen P. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer 2013;109:2941-50.
Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, Verhoef VM, et al. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. Int J Cancer 2016;139:691-9.
Hammer A, Rositch A, Qeadan F, Gravitt PE, Blaakaer J. Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis. Int J Cancer 2016;138:2795-803.
De Sanjose S, Quint WG, Allemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, et al. A cohort study of cervical screening using partial HPV typing and cytology triage. Int J Cancer 2016;139:2606-15.
Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Srisomboon J, Intaraphet S, et al. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 has a higher performance than HPV16/18 genotyping in triaging women with positive high-risk HPV test in Northern Thailand. PLoS ONE 2016;11:e0158184.
Cuzick J, Wheeler C. Need for expanded HPV genotyping for cervical screening. Papillomavirus Res 2016;2:112-5.
Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
European Medicines Agency. Cervarix. Procedural steps taken and scientific information after the authorisation. EMA/620356/2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Procedural_steps_taken_and_scientific_information_after_authorisation/human/000721/WC500024639.pdf (Accessed 10/01/2019)